JP2009532340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532340A5 JP2009532340A5 JP2009501780A JP2009501780A JP2009532340A5 JP 2009532340 A5 JP2009532340 A5 JP 2009532340A5 JP 2009501780 A JP2009501780 A JP 2009501780A JP 2009501780 A JP2009501780 A JP 2009501780A JP 2009532340 A5 JP2009532340 A5 JP 2009532340A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- tau protein
- selenate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 102000013498 tau Proteins Human genes 0.000 claims 8
- 108010026424 tau Proteins Proteins 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 210000004498 neuroglial cell Anatomy 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 2
- 206010036631 Presenile dementia Diseases 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960004502 levodopa Drugs 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 230000006951 hyperphosphorylation Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960004851 pergolide Drugs 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229940063238 premarin Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001282 primary progressive aphasia Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- -1 risridine Chemical compound 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
- 229960004479 trihexyphenidyl hydrochloride Drugs 0.000 claims 1
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78724006P | 2006-03-29 | 2006-03-29 | |
| US60/787,240 | 2006-03-29 | ||
| PCT/AU2007/000391 WO2007109851A1 (en) | 2006-03-29 | 2007-03-29 | Treatment of neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009532340A JP2009532340A (ja) | 2009-09-10 |
| JP2009532340A5 true JP2009532340A5 (enExample) | 2010-05-13 |
| JP5542430B2 JP5542430B2 (ja) | 2014-07-09 |
Family
ID=38540722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501780A Expired - Fee Related JP5542430B2 (ja) | 2006-03-29 | 2007-03-29 | 神経変性疾患の治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8920851B2 (enExample) |
| EP (1) | EP2004204B1 (enExample) |
| JP (1) | JP5542430B2 (enExample) |
| KR (1) | KR101451439B1 (enExample) |
| CN (1) | CN101478977B (enExample) |
| AU (1) | AU2007231547B2 (enExample) |
| BR (1) | BRPI0709033A2 (enExample) |
| CA (1) | CA2644441C (enExample) |
| DK (1) | DK2004204T3 (enExample) |
| ES (1) | ES2394348T3 (enExample) |
| MX (1) | MX2008012479A (enExample) |
| NZ (2) | NZ571835A (enExample) |
| RU (1) | RU2489155C2 (enExample) |
| WO (1) | WO2007109851A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4991544B2 (ja) | 2004-08-23 | 2012-08-01 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | ストレス応答を媒介するためのペプチド阻害剤 |
| CN101478977B (zh) | 2006-03-29 | 2013-03-27 | 维拉科治疗学控股有限公司 | 神经变性疾病的治疗 |
| US20100247679A1 (en) * | 2006-04-24 | 2010-09-30 | Alltech, Inc. | Methods and compositions for altering cell function |
| EP2012806A4 (en) * | 2006-04-24 | 2010-07-28 | Alltech Inc | METHOD AND COMPOSITIONS FOR MODIFYING CELL FUNCTIONS |
| WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| WO2009039586A2 (en) * | 2007-09-28 | 2009-04-02 | Powmri Limited | Biomarkers for parkinson's disease |
| WO2009043116A1 (en) * | 2007-10-03 | 2009-04-09 | Velacor Therapeutics Pty Ltd | Methods and compositions for the treatment of phosphatase- related disorders |
| WO2009043106A1 (en) * | 2007-10-03 | 2009-04-09 | Velacor Therapeutics Pty Ltd | Inorganic selenium and angiogenesis |
| WO2009065596A2 (en) * | 2007-11-22 | 2009-05-28 | Develogen Aktiengesellschaft | Use of mnk inhibitors for the treatment of alzheimer's disease |
| JP5328244B2 (ja) * | 2008-07-07 | 2013-10-30 | 株式会社ニュージェン・ファーマ | 筋萎縮性側索硬化症治療剤 |
| JP2013507352A (ja) * | 2009-10-09 | 2013-03-04 | テバ ファーマシューティカル インダストリーズ リミティド | 進行性核上性麻痺の治療のためのラサギリンの使用 |
| WO2012160563A2 (en) | 2011-05-23 | 2012-11-29 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| JP6659050B2 (ja) | 2015-03-26 | 2020-03-04 | スーヂョウ アウゾン バイオロジカル テクノロジー カンパニー， リミテッド | Ｐ７５ｅｃｄ及び／又はｐ７５による神経学的障害の診断又は処置方法 |
| WO2019216589A1 (ko) * | 2018-05-09 | 2019-11-14 | 한국과학기술연구원 | 타우 관련 질환의 예방 또는 치료용 조성물 |
| EP3813882B1 (en) * | 2018-06-29 | 2023-08-09 | Rejuvenate Biomed | Pharmaceutical combination comprising a biguanid and an acetylcholinesterase inhibitor for use in age-related and/or degenerative diseases |
| WO2020198209A1 (en) | 2019-03-26 | 2020-10-01 | Seer, Inc. | Compositions, methods and systems for protein corona analysis from biofluids and uses thereof |
| WO2023029210A1 (zh) * | 2021-08-31 | 2023-03-09 | 上海交通大学医学院附属瑞金医院 | Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍 |
| WO2023057422A1 (en) * | 2021-10-06 | 2023-04-13 | Bayer Aktiengesellschaft | Universal buffer in methods for safe and rapid detection of pathogen infection |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601915D0 (en) | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| JPH04247033A (ja) * | 1991-02-04 | 1992-09-03 | Yoshitomi Pharmaceut Ind Ltd | 神経細胞壊死抑制剤 |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5695752A (en) * | 1992-09-11 | 1997-12-09 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
| CA2185324A1 (en) | 1994-03-16 | 1995-09-21 | Steven D. Rosen | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
| US6524619B2 (en) * | 2000-01-27 | 2003-02-25 | Chronorx, Inc. | Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus |
| DE10059886A1 (de) * | 2000-12-01 | 2002-06-20 | Basf Coatings Ag | Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen |
| GB0202900D0 (en) | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
| US7304071B2 (en) * | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| JP2006525329A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換カルボン酸類 |
| AU2003904328A0 (en) | 2003-08-13 | 2003-08-28 | Garvan Institute Of Medical Research | Diagnosis and treatment of neurodegenerative disorders |
| US20070026090A1 (en) * | 2003-09-05 | 2007-02-01 | Oren Tirosh | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| US20050142216A1 (en) * | 2003-12-31 | 2005-06-30 | Rindlesbach Keith A. | Method for reversing Alzheimer dementia |
| CN101073584B (zh) * | 2005-10-14 | 2012-10-10 | 全面技术公司 | 改变细胞功能的方法和组合物 |
| US20080004255A1 (en) * | 2005-10-14 | 2008-01-03 | Alltech, Inc. | Methods and compositions for altering cell function |
| CN101478977B (zh) | 2006-03-29 | 2013-03-27 | 维拉科治疗学控股有限公司 | 神经变性疾病的治疗 |
| AU2007231549A1 (en) | 2006-03-29 | 2007-10-04 | Velacor Therapeutics Pty Ltd | Inorganic selenium for treatment of benign tumors |
-
2007
- 2007-03-29 CN CN2007800122806A patent/CN101478977B/zh not_active Expired - Fee Related
- 2007-03-29 US US12/295,270 patent/US8920851B2/en not_active Expired - Fee Related
- 2007-03-29 KR KR1020087026561A patent/KR101451439B1/ko not_active Expired - Fee Related
- 2007-03-29 WO PCT/AU2007/000391 patent/WO2007109851A1/en not_active Ceased
- 2007-03-29 BR BRPI0709033-1A patent/BRPI0709033A2/pt not_active IP Right Cessation
- 2007-03-29 MX MX2008012479A patent/MX2008012479A/es active IP Right Grant
- 2007-03-29 RU RU2008142514/15A patent/RU2489155C2/ru not_active IP Right Cessation
- 2007-03-29 ES ES07718638T patent/ES2394348T3/es active Active
- 2007-03-29 NZ NZ571835A patent/NZ571835A/en not_active IP Right Cessation
- 2007-03-29 EP EP07718638A patent/EP2004204B1/en not_active Not-in-force
- 2007-03-29 JP JP2009501780A patent/JP5542430B2/ja not_active Expired - Fee Related
- 2007-03-29 CA CA2644441A patent/CA2644441C/en not_active Expired - Fee Related
- 2007-03-29 NZ NZ596244A patent/NZ596244A/xx not_active IP Right Cessation
- 2007-03-29 AU AU2007231547A patent/AU2007231547B2/en not_active Ceased
- 2007-03-29 DK DK07718638.5T patent/DK2004204T3/da active
-
2013
- 2013-11-14 US US14/079,877 patent/US20140141104A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009532340A5 (enExample) | ||
| RU2489155C2 (ru) | Лечение нейродегенеративных заболеваний | |
| EP2468271B1 (en) | Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia | |
| RU2394570C2 (ru) | Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств | |
| JP2011522035A5 (enExample) | ||
| ES2638190T3 (es) | Métodos para tratar la dependencia | |
| AU2013224960B2 (en) | New therapeutic approaches for treating Parkinson's disease | |
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| BRPI0608205B8 (pt) | derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor | |
| JP2014205696A (ja) | 細胞ストレス応答の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ | |
| MX2008001711A (es) | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa. | |
| JP2006522800A5 (enExample) | ||
| US20140315786A1 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
| JP2009534312A5 (enExample) | ||
| WO2007078874A3 (en) | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors | |
| JP2016210798A5 (enExample) | ||
| JP2007536311A5 (enExample) | ||
| CO6640335A2 (es) | Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes | |
| UY27991A1 (es) | Derivados de pirrolidona domo inhibidores de maob | |
| Moo-Puc et al. | Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy | |
| Borbe et al. | Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat | |
| US10765630B2 (en) | Methods and compositions to treat enteropathic arthritis | |
| KR20140131335A (ko) | 드록시도파를 투여하는, 자세 안정성 개선 방법 | |
| Tabi et al. | The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease | |
| Saavedra et al. | Huntington’s disease: novel therapeutic perspectives hanging in the balance |